Chronic Liver Failure model

Indication / Application

Efficacy testing of therapies targeting decompensated liver cirrhosis, screening of agents to prevent acute-on-chronic liver failure (ACLF), validation of liver-regenerative drugs, and preclinical safety/efficacy profiling of liver support systems or cell therapies.

Modeling Method

1. Chemical-Induced Decompensated Cirrhosis Model:

• Rodents receive chronic administration of hepatotoxic agents (such as carbon tetrachloride) over an extended period. This prolonged chemical insult drives diffuse hepatocyte necrosis, persistent lobular inflammation, and progressive bridging fibrosis, ultimately culminating in micronodular cirrhosis and metabolic decompensation.

2. Bile Duct Ligation (BDL) Model (Biliary Cirrhosis & Cholestatic Failure):

• Under aseptic surgical conditions, a midline laparotomy is performed. The common bile duct is isolated, ligated, and transected. Chronic bile duct obstruction leads to rapid biliary epithelial proliferation, severe portal tract inflammation, and progressive biliary cirrhosis, resulting in functional hepatic decompensation within several weeks.

3. Secondary Acute Challenge (Acute-on-Chronic Liver Failure / ACLF):

• Chronically preconditioned animals (via chemical induction or surgical BDL) are subjected to a secondary acute challenge to induce a systemic inflammatory response syndrome (SIRS) and precipitate acute-on-chronic hepatic failure.

Clinical Relevance

• Pathological Match: These models successfully replicate the clinical progression of human end-stage liver disease, demonstrating classical hallmarks such as ascites accumulation, splenomegaly, impaired protein synthesis (hypoalbuminemia), and prolonged coagulation times.

• Hepatic Encephalopathy (HE): The marked hyperammonemia observed in advanced decompensation regimens provides a translational system to study secondary neurotoxicity and test HE-targeted therapies.

• Multi-System Complications: Replicates systemic complications of clinical liver failure, including renal dysfunction and systemic inflammatory responses.

Key Evaluation Endpoints

In Vivo & Physical Parameters

• Survival Rate Monitoring: Tracking of long-term survival curves under therapeutic intervention.

• Ascites Quantitation: Assessment of ascites incidence, volume collection, and protein/cellular content.

• Hepatic Encephalopathy Scoring: Behavioral testing evaluating motor function and reflexes to assess neurocognitive decline.

Serum Biochemistry & Coagulation Panels (Functional Indicators)

• Hepatic Secretory & Metabolic Function: Serial blood sampling to measure liver enzymes (ALT, AST), Total Bilirubin (TBIL), Serum Albumin (ALB), and Blood Ammonia.

• Coagulation Profiling: Measurement of Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) to evaluate hepatic synthetic reserve and coagulopathy.

• Renal Functional Monitoring: Analysis of Serum Creatinine (Cr) and Blood Urea Nitrogen (BUN) to screen for secondary renal impairment.

Histopathology & Fibrosis Quantitation (Microstructural Analysis)

• Histomorphological Assessment: Standard H&E staining to grade lobular necrosis, ductular reaction, and inflammatory infiltration.

• Fibrosis Progression Scoring: Histochemical staining (such as Masson's Trichrome, Sirius Red) paired with digital image analysis to quantify collagen deposition and assess nodular parenchymal architecture.

Inflammatory & Molecular Biomarkers

• Fibrogenic Signaling Pathway Analysis: Gene and protein expression profiling of key fibrotic markers (alpha-SMA, Collagen Type I, and TGF-beta).

• Localized Inflammatory Cytokines: Quantification of hepatic and systemic pro-inflammatory cytokines (such as TNF-alpha, IL-1beta, IL-6) and tissue oxidative stress markers.